| Previous Close | 0.59 |
| Open | 0.58 |
| Bid | 0.59 x 0 |
| Ask | 0.60 x 0 |
| Day's Range | 0.58 - 0.60 |
| 52 Week Range | 0.55 - 2.02 |
| Volume | 63,250 |
| Avg. Volume | 81,350 |
| Market Cap | 43.72M |
| Beta | 4.52 |
| PE Ratio (TTM) | 38.67 |
| EPS (TTM) | 0.01 |
| Earnings Date | Nov 21, 2017 - Nov 27, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Capital Cube•20 days agoCeapro, Inc.: Sudden move in price, will it continue?
Categories: Yahoo FinanceCeapro, Inc. relative valuation is UNDERVALUED and it has a fundamental analysis score of 84. Our analysis is based on comparing Ceapro, Inc. with the following peers – Microbix Biosystems Inc., ProMetic Life Sciences Inc., GeneNews Limited, Medicure Inc., Sirona Biochem Corp., Med BioGene Inc., Critical Outcome Technologies Inc. and Generex Biotechnology Corporation (MBX-CA, PLI-CA, ... Read more (Read more...)
Capital Cube•28 days agoCeapro, Inc. :CZO-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017
Categories: Yahoo FinanceGet free summary analysis Ceapro, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Ceapro, Inc. – ProMetic Life Sciences Inc., GeneNews Limited and Medicure Inc. (PLI-CA, GEN-CA and MPH-CA) that have also reported for this period. Highlights Summary numbers: Revenues of CAD ... Read more (Read more...)
- Marketwired•last month
Ceapro Reports 2017 Second Quarter Business Update and Financial Results
Ceapro Inc. a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for ...
